Area of research
Genetics · Hematology
Research interest
Research interests include Coagulation, Bradykinin, Polyphosphates, and Angioedema, Hemophilia Treatment and Research, Complement system in diseases, and Urticaria and Related Conditions.
Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment
Establishing a hereditary angioedema prevalence for the United States using a large administrative claims database
Patient‐Reported Outcomes in the Phase III OASIS‐HAE Study of Donidalorsen for Hereditary Angioedema
Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 inhibitor
Diagnostic testing for chronic spontaneous urticaria with or without angioedema: The do's, don't and maybe's
Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis
Lanadelumab for prevention of attacks of non-histaminergic normal C1 inhibitor angioedema: results from the randomized, double-blind CASPIAN Study and CASPIAN open-label extension
Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension
Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks
The future of therapeutic options for hereditary angioedema
Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelines
Clinical burden, treatment, and disease control in patients with chronic spontaneous urticaria
Development and validation of a US quality of life instrument for hereditary angioedema due to C1 inhibitor deficiency
The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation
Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: Results of the Double-blind, Placebo-controlled Phase 3 KONFIDENT Trial
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial
Hereditary Angioedema With Normal C1 Inhibitor: US Survey of Prevalence and Provider Practice Patterns
Urticaria and Angioedema: Understanding Complex Pathomechanisms to Facilitate Patient Communication, Disease Management, and Future Treatment
A phase 2 <scp>open‐label</scp> extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema
Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema
Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema
Efficacy And Safety Of Bradykinin B2 Receptor Inhibition With Oral PHVS416 In Treating Hereditary Angioedema Attacks: Results Of RAPIDe-1 Phase 2 Trial
Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update
The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
Inhibition of Prekallikrein for Hereditary Angioedema
Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report
Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
Consensus on treatment goals in hereditary angioedema: A global Delphi initiative